External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
W.B. Saunders Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ?15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification. Method: It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan–Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching. Results: After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP?15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP?15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated. Conclusion: the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients. © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
Açıklama
Anahtar Kelimeler
Antineoplastic Agent, Ki 67 Antigen, Ki 67 Antigen, Adjuvant Chemotherapy, Adult, Aged, Article, Cancer Classification, Cancer Patient, Cancer Survival, Cell Density, Cohort Analysis, Controlled Study, Cytoreductive Surgery, Disease Free Survival, Female, Follow Up, Human, Human Tissue, Hyperthermic İntraperitoneal Chemotherapy, Labeling İndex, Major Clinical Study, Male, Median Survival Time, Multicenter Study, Neoadjuvant Chemotherapy, Overall Survival, Peritoneum Pseudomyxoma, Predictive Value, Proliferation İndex, Prospective Study, Receiver Operating Characteristic, Survival Rate, Systemic Therapy, Tissue Section, Validation Process, Clinical Trial, Pathology, Peritoneum Pseudomyxoma, Peritoneum Tumor, Prognosis, Proportional Hazards Model, Retrospective Study, Humans, Ki-67 Antigen, Peritoneal Neoplasms, Prognosis, Proportional Hazards Models, Pseudomyxoma Peritonei, Retrospective Studies
Kaynak
European Journal of Surgical Oncology
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
49
Sayı
8
